Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Musculoskeletal disease

Osteoporosis

Hypoxia-inducible
factor 1a
(HIF1A; HIF1a)

Mouse studies suggest HIF1A inhibitors could help prevent postmenopausal osteoporosis. In the ovariectomized mouse model of osteoporosis, compared with sham-operated animals, estrogen deficiency increased Hif1a levels in osteoclasts. In the same model, a HIF1A inhibitor decreased osteoclast activation and increased bone mineral density compared with vehicle. Next steps could include determining mechanisms of estrogen-mediated HIF1A regulation.
At least seven companies have HIF1A inhibitors in Phase II or earlier testing to treat various cancers.

SciBX 6(39); doi:10.1038/scibx.2013.1101
Published online Oct. 10, 2013

Patent application filed; licensing details available from Keio University

Miyauchi, Y. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 10, 2013;
doi:10.1073/pnas.1308755110
Contact: Takeshi Miyamoto, Keio University, Tokyo, Japan
e-mail:

miyamoto@z5.keio.jp